Member Info for Surin

Sorry to hear that. I had a simple cataract operation and I lost sight in my left eye...medical science can be hit and miss.

Wibble, indeed. The fixed costs have been sunk...scale up will be utilizing sunk investments for sales...

Quite a crucial time for OBD

Yes not much difference, assuming you take out complications, false positives, false negatives etc. Also we assume there are no other applications. Finally I wonder why Medicaid and BUPA have approved it if not cost effective. No answers, I am only a small late investor/ bottom feeder who like the technology. Any comments/infor would be good for informing and evaluating the risk/reward profile of OBD. I I may start-

Pros a)has a verifiably proven and applied technology (in use test) b) application, with high efficacy for prostrate cancer c) recent study by large pharma (with a large sample size) show valuable diagnostic/prognostic efficacy for other cancers. d) has reputable, blue chip and cross continent partners e) seems well networked across blue chip companies and world class scientific centers.

Cons a) Already high sunk costs but nascent adoption b) Overheads of staff, building and general infratructure related to testing unable to be covered by sales c) appears will need funding unless can develop joint ventures . d) susceptible to cheap IP takeover

As has been said ...not a question of IF, more a question of WHEN

Https://prostatecanceruk.org/about-us/news-and-views/2025/04/health-secretary-backs-screening

Why not just takeover the IP?

Just google episwitch. Also note Trafalgar HK (not uk). Then look at prostrate cancer incidences and china...

Surely the cost needs to be balanced with savings/ benefits...so complete your calculation...

Davidlen. You did enough ramping yesterday...have you not had your fill?

Https://www.ainvest.com/news/oxford-biodynamics-episwitch-a-non-invasive-breakthrough-in-cancer-diagnostics-fueling-a-stock-surge-2507101036f40ea05347019e/

balanced article for me...

Results are research based. The `technology' needs to be applied and rolled out. Research conirmation via big pharma...well its big news...

If OBD, with partners, can deliver the research findings in the `field'/application, £16m market cap is a nonsense

Cricket, research confirmed by big pharma is a big thing

Is there a ramping crew about? These people have no shame, and have no care/respect for what some folk are trying to do to advance their research. No wonder the UK is in the mess it is!

If this was a David Lenigas I would be out like a shot...hope there is no connection...dont think Big Pharma would entertain him...so no worries

Davgid Lenigas? God save us...

Stop the ramping, if you had faith and were a long term holder - you would be quietly satisfied

CXheap UK stocks available owing to the short termist dealings/orientation of the city of London. OBD must be a cheap buy/takeover target

Correct, was why I bought in...but sp subsequently collapsed by almost 50%...crazy

...or be taken over...